NCT00381797 2017-11-28Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade GliomaNational Cancer Institute (NCI)Phase 2 Completed97 enrolled 35 charts